Findings from pharmacogenomics (PGx) studies have the potential to be applied to individualize drug therapy to improve efficacy and reduce adverse drug events. Researchers have identified factors influencing uptake of genomics in medicine, but little is known about the specific technical barriers to incorporating PGx into existing clinical frameworks. We present the design and development of a prototype PGx clinical decision support (CDS) system that builds on existing clinical infrastructure and incorporates semi-active and active CDS. Informing this work, we updated previous evaluations of PGx knowledge characteristics, and of how the CDS capabilities of three local clinical systems align with data and functional requirements for PGx CDS. We summarize characteristics of PGx knowledge and technical needs for implementing PGx CDS within existing clinical frameworks. PGx decision support rules derived from FDA drug labels primarily involve drug metabolizing genes, vary in maturity, and the majority support the post-analytic phase of genetic testing. Computerized provider order entry capabilities are key functional requirements for PGx CDS and were best supported by one of the three systems we evaluated. We identified two technical needs when building on this system, the need for (1) new or existing standards for data exchange to connect clinical data to PGx knowledge, and (2) a method for implementing semi-active CDS. Our analyses enhance our understanding of principles for designing and implementing CDS for drug therapy individualization and our current understanding of PGx characteristics in a clinical context. Characteristics of PGx knowledge and capabilities of current clinical systems can help govern decisions about CDS implementation, and can help guide decisions made by groups that develop and maintain knowledge resources such that delivery of content for clinical care is supported.
References
[1]
Baars, M.J.; Henneman, L.; Ten Kate, L.P. Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: A global problem. Genet. Med. 2005, 7, 605–610.
[2]
Menasha, J.; Schechter, C.; Willner, J. Genetic testing: A physician’s perspective. Mt. Sinai J. Med. 2000, 67, 144–151.
[3]
Personalized Healthcare Detailed Use Case. Available online: http://healthit.hhs.gov/portal/server.pt/gateway/PTARGS_0_10731_848111_0_0_18/PHCDetailed.pdf (accessed on 11 October 2012).
[4]
Overby, C.; Tarczy-Hornoch, P.; Hoath, J.; Kalet, I.; Veenstra, D. Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. BMC Bioinform. 2010, 11 Suppl. 9, S10.
[5]
Overby, C.; Tarczy-Hornoch, P.; Hoath, J.; Smith, J.; Fenstermacher, D.; Devine, E. An evaluation of functional and user interface requirements for pharmacogenomic clinical decision support. In Proceedings of 2011 First IEEE International Conference on Health Informatics, Imaging, and Systems Biology (HISB), San Jose, CA, USA, 26–29 July, 2011.
[6]
US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labels. (updated May 2011). 2011. Available online: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm (accessed on 11 October 2012).
[7]
Wright, A.; Goldberg, H.; Hongsermeier, T.; Middleton, B. A description and functional taxonomy of rule-based decision support content at a large integrated delivery network. J. Am. Med. Inform. Assoc. 2007, 14, 489–496, doi:10.1197/jamia.M2364.
[8]
Del Fiol, G.; Kawamoto, K.; Cimino, J.J. Open-source, standards-based software to enable decision support. Proc. AMIA Annu. Fall Symp. 2011, 2011, 2127.
[9]
Openinfobutton Project Webpage, Available online: http:www.openinfobutton.org (accessed on 11 October 2012).
[10]
Discern Expert？. Cerner Coorporation, Kansas City, MO, USA, 2011.
[11]
US Centers for Disease Control and Prevention. CDC Summaries of EGAPP Recommendation Statements (last updated 13 January 2011). Available online: http://www.cdc.gov/genomics/gtesting/EGAPP/recommend/ (accessed on 11 October 2012).
[12]
Gwinn, M.; Dotson, W.D.; Khoury, M.J. Plos currents: Evidence on genomic tests—At the crossroads of translation. PLoS Curr. 2010, 2.
[13]
Relling, M.V.; Klein, T.E. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 2011, 89, 464–467, doi:10.1038/clpt.2010.279.
[14]
Hughes, S. Vanderbilt now also routinely gene testing for clopidogrel metabolizer status. HeartWire 2010.
[15]
US National Library of Medicine. DailyMed Website. Available online: http://dailymed.nlm.nih.gov/dailymed/about.cfm (accessed on 11 October 2012).
[16]
The Pharmacogenomics Knowledge Base [PharmGKB] Website. Available online: http://pharmgkb.org (accessed on 18 October 2012).
[17]
Hernandez-Boussard, T.; Whirl-Carrillo, M.; Hebert, J.M.; Gong, L.; Owen, R.; Gong, M.; Gor, W.; Liu, F.; Truong, C.; Whaley, R.; et al. The pharmacogenetics and pharmacogenomics knowledge base: Accentuating the knowledge. Nucleic Acids Res. 2008, 36, D913–D918.
[18]
Hachad, H.; Overby, C.L.; Argon, S.; Yeung, C.K.; Ragueneau-Majlessi, I.; Levy, R.H. E-pkgene: A knowledge-based research tool for analysing the impact of genetics on drug exposure. Hum. Genomics 2011, 5, 506–515, doi:10.1186/1479-7364-5-5-506.
[19]
Del Fiol, G.; Williams, M.; Maram, N.; Rocha, R.; Wood, G.; Mitchell, J. Integrating genetic information resources with an ehr. Proc. AMIA Annu. Symp. 2006, 2006, 904.
[20]
Kaihoi, B.; Petersen, C.; Bolander, M. Providing "just-in-time" medical genomics information for patient care. Proc. AMIA Annu. Symp. 2005, 2005, 1003.
[21]
Maviglia, S.; Yoon, C.; Bates, D.; Kuperman, G. Knowledgelink: Impact of context-sensitive information retrieval on clinicians’ information needs. J. Am. Med. Inform. Assoc. 2006, 13, 67–73.
[22]
US Department of Health and Human Services. Personalized Health Care: Pioneers, Partnerships, Progress. Available online: http:www.hhs.gov/myhealthcare/news/phc_2008_report.pdf (accessed on 11 October 2012).
[23]
Relling, M. Delivery of information: Implementation of pharmacogenomics in clinical practice. In Presented at Integrating Large-Scale Genomic Information into Clinical Practice: A Workshop, Washington, DC, USA, 19 July 2011.
[24]
Vnencak-Jones, C. Pharmacogenetics: From DNA to dosage—Just a click away. In Presented at Operationalizing Innovation: Where the Cutting Edge Meets Current Practice (CAP Foundation Confernce Series IV), Rosemont, IL, USA, 15–17 April 2011.
[25]
Frueh, F.; Amur, S.; Mummaneni, P.; Epstein, R.; Aubert, R.; DeLuca, T.; Verbrugge, R.; Burckart, G.; Lesko, L. Pharmacogenomic biomarker information in drug labels approved by the united states food and drug administration: Prevalence of related drug use. Pharmacotherapy 2008, 28, 992–998, doi:10.1592/phco.28.8.992.
[26]
Deverka, P.; Doksum, T.; Carlson, R. Integrating molecular medicine into the us health-care system: Opportunities, barriers, and policy challenges. Clin. Pharmacol. Ther. 2007, 82, 427–434, doi:10.1038/sj.clpt.6100319.
[27]
Context-aware knowledge retrieval (infobutton) product brief. HL7 International Wiki Site. Available online: http://wiki.hl7.org/index.php?title=Product_Infobutton (accessed on 11 October 2012).
[28]
Health Information Technology: Standards, Implementation Specifications, and Certification Criteria for Electronic Health Record Technology, 2014 edition; revisions to the permanent certification program for health information technology. In 45 CFR Part 170; Office of the National Coordinator for Health Information Technology (ONC), Department of Health and Human Services: Washington, D.C., USA, 2012.
[29]
Del Fiol, G.; Huser, V.; Strasberg, H.R.; Maviglia, S.M.; Curtis, C.; Cimino, J.J. Implementations of the HL7 context-aware knowledge retrieval ("infobutton") standard: Challenges, strengths, limitations, and uptake. J. Biomed. Inform. 2012, 45, 726–735.
